Opinion
A look at whether big money and big deals will be in store for 2018.
Here are some thoughts on breaking into the biomechanical engineering market.
A look at the latest batch of FDA approvals this year.
The company’s vaccine controversy could cause legal and image problems for years to come.
A look at what three ex-Genentech employees have accomplished at Denali so far.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
One of the biggest concerns has been the loss of the R&D tax credit, which incentivizes companies, including life science firms, to support research.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.